オンコリスバイオファーマ(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証GRT | 医薬品 | 4588/ - | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2015/04/03 | 日証協 | 837,375株 | -1.08% | 7,400株 | -65.72% | 512,545株 | -0.41% | 1,700株 | -71.19% |
2015/03/20 | 日証協 | 858,175株 | -5.2% | 45,790株 | +217.99% | 515,045株 | -4.56% | 8,000株 | +294.09% |
2015/03/13 | 日証協 | 905,275株 | +1.26% | 14,400株 | -61.07% | 539,645株 | -0.55% | 2,030株 | -90.81% |
2015/03/06 | 日証協 | 894,005株 | -1.27% | 36,990株 | -7.96% | 542,645株 | -7.63% | 22,100株 | +169.51% |
2015/02/27 | 日証協 | 905,505株 | -1.2% | 40,190株 | +22.16% | 587,445株 | -0.64% | 8,200株 | -69.52% |
2015/02/20 | 日証協 | 916,505株 | -0.51% | 32,900株 | +96.3% | 591,245株 | +1.04% | 26,900株 | -50.94% |
2015/02/13 | 日証協 | 921,235株 | +0.17% | 16,760株 | -71.73% | 585,175株 | +0.95% | 54,830株 | +63.53% |
2015/02/06 | 日証協 | 919,675株 | +2.2% | 59,290株 | -30.98% | 579,645株 | +8.25% | 33,530株 | -66.4% |
2015/01/30 | 日証協 | 899,905株 | -7.05% | 85,900株 | +549.28% | 535,445株 | -7.77% | 99,800株 | +1127.55% |
2015/01/23 | 日証協 | 968,205株 | +0.56% | 13,230株 | -45.1% | 580,545株 | +1.49% | 8,130株 | -48.22% |
2015/01/16 | 日証協 | 962,805株 | +1.5% | 24,100株 | -56.36% | 572,045株 | +1.02% | 15,700株 | +127.54% |
2015/01/09 | 日証協 | 948,605株 | -6.13% | 55,220株 | +1392.43% | 566,245株 | -2.35% | 6,900株 | -47.76% |
2014/12/30 | 日証協 | 1,010,580株 | +0.67% | 3,700株 | -94.5% | 579,846株 | -2.69% | 13,209株 | -62.04% |
2014/12/26 | 日証協 | 1,003,880株 | +3.92% | 67,270株 | -21.87% | 595,845株 | +4.75% | 34,800株 | +125.97% |
2014/12/19 | 日証協 | 966,010株 | +2.02% | 86,095株 | +27.94% | 568,845株 | +2.75% | 15,400株 | +54% |
2014/12/12 | 日証協 | 946,910株 | -6.73% | 67,295株 | +27.69% | 553,645株 | -6.64% | 10,000株 | -48.45% |
2014/12/05 | 日証協 | 1,015,215株 | +4.2% | 52,700株 | -68.02% | 593,050株 | +3.6% | 19,400株 | -81.52% |
2014/11/28 | 日証協 | 974,315株 | -10.16% | 164,800株 | +405.44% | 572,451株 | -14.12% | 104,955株 | +27.53% |
2014/11/21 | 日証協 | 1,084,510株 | -2% | 32,605株 | -73.25% | 666,546株 | +3.48% | 82,300株 | +290.05% |
※株式分割は考慮していませんのでご注意ください。
Page Top